 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced it will present data from the pivotal Phase 3 clinical trial STRATA2016 of its investigational product StrataGraft, a regenerative skin tissue therapy in development for the treatment of deep partial-thickness thermal burns, as well as health economics and outcomes research HEOR and other data on the treatment of burns as part of the virtual American Burn Association ABA 52nd Annual Meeting. The virtual meeting begins today and is accessible online for attendees during the next 90 days. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration FDA. 